Literature DB >> 8437700

Methylprednisolone selectively affects dystrophin expression in human muscle cultures.

O Hardiman1, R M Sklar, R H Brown.   

Abstract

Glucocorticoid therapy slows the progression of Duchenne muscular dystrophy. In muscle cultures, the addition of the glucocorticoid methylprednisolone increases myogenesis in most normal mixed and clonal cultures. Conversely, in some normal clonal and most dystrophic cultures, methylprednisolone inhibits fusion. However, in fusion-arrested normal and Becker muscular dystrophy cultures, dystrophin is expressed independently of fusion and of myosin heavy chain expression, and in some cases, expression is apparently enhanced by methylprednisolone. We suggest that dystrophin is a muscle-specific protein that does not require fusion for expression, and the methylprednisolone-induced enhancement of dystrophin expression may account for some of the clinical benefits of glucocorticoids in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437700     DOI: 10.1212/wnl.43.2.342

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Prednisone can protect against exercise-induced muscle damage.

Authors:  S C Jacobs; A L Bootsma; P W Willems; P R Bär; J H Wokke
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

Review 2.  Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.

Authors:  Corrado Angelini; Enrico Peterle
Journal:  Acta Myol       Date:  2012-05

Review 3.  Corticosteroid Treatment Impact on Spinal Deformity in Duchenne Muscular Dystrophy.

Authors:  Ilaria Sanzarello; Luciano Merlini; Francesco Traina; Michele Attilio Rosa; Cesare Faldini
Journal:  Int Sch Res Notices       Date:  2014-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.